Switch to:
Also traded in: Germany, Singapore, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.09
LZAGY's Cash to Debt is ranked lower than
92% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. LZAGY: 0.09 )
Ranked among companies with meaningful Cash to Debt only.
LZAGY' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.15 Max: 0.85
Current: 0.09
0.06
0.85
Equity to Asset 0.33
LZAGY's Equity to Asset is ranked lower than
80% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. LZAGY: 0.33 )
Ranked among companies with meaningful Equity to Asset only.
LZAGY' s Equity to Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.33 Max: 0.5
Current: 0.33
0.3
0.5
F-Score: 7
Z-Score: 2.30
M-Score: -2.68
WACC vs ROIC
8.66%
8.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.62
LZAGY's Operating margin (%) is ranked higher than
80% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. LZAGY: 11.62 )
Ranked among companies with meaningful Operating margin (%) only.
LZAGY' s Operating margin (%) Range Over the Past 10 Years
Min: 7.06  Med: 11.70 Max: 15.02
Current: 11.62
7.06
15.02
Net-margin (%) 6.51
LZAGY's Net-margin (%) is ranked higher than
74% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. LZAGY: 6.51 )
Ranked among companies with meaningful Net-margin (%) only.
LZAGY' s Net-margin (%) Range Over the Past 10 Years
Min: 2.43  Med: 6.99 Max: 14.27
Current: 6.51
2.43
14.27
ROE (%) 11.14
LZAGY's ROE (%) is ranked higher than
77% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. LZAGY: 11.14 )
Ranked among companies with meaningful ROE (%) only.
LZAGY' s ROE (%) Range Over the Past 10 Years
Min: 4.11  Med: 11.75 Max: 22.52
Current: 11.14
4.11
22.52
ROA (%) 3.70
LZAGY's ROA (%) is ranked higher than
65% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. LZAGY: 3.70 )
Ranked among companies with meaningful ROA (%) only.
LZAGY' s ROA (%) Range Over the Past 10 Years
Min: 1.3  Med: 4.30 Max: 7.45
Current: 3.7
1.3
7.45
ROC (Joel Greenblatt) (%) 13.67
LZAGY's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. LZAGY: 13.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LZAGY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 7.93  Med: 13.76 Max: 29.49
Current: 13.67
7.93
29.49
Revenue Growth (3Y)(%) 10.30
LZAGY's Revenue Growth (3Y)(%) is ranked higher than
69% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. LZAGY: 10.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LZAGY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.5  Med: 8.65 Max: 12.8
Current: 10.3
-5.5
12.8
EBITDA Growth (3Y)(%) 10.20
LZAGY's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. LZAGY: 10.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LZAGY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.4  Med: 4.55 Max: 20.9
Current: 10.2
-12.4
20.9
EPS Growth (3Y)(%) 15.20
LZAGY's EPS Growth (3Y)(%) is ranked higher than
75% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. LZAGY: 15.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LZAGY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.9  Med: -1.25 Max: 29.5
Current: 15.2
-32.9
29.5
» LZAGY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with LZAGY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 31.00
LZAGY's P/E(ttm) is ranked higher than
54% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.30 vs. LZAGY: 31.00 )
Ranked among companies with meaningful P/E(ttm) only.
LZAGY' s P/E(ttm) Range Over the Past 10 Years
Min: 8.61  Med: 22.09 Max: 69.7
Current: 31
8.61
69.7
Forward P/E 18.05
LZAGY's Forward P/E is ranked higher than
55% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.02 vs. LZAGY: 18.05 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.00
LZAGY's PE(NRI) is ranked higher than
50% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. LZAGY: 31.00 )
Ranked among companies with meaningful PE(NRI) only.
LZAGY' s PE(NRI) Range Over the Past 10 Years
Min: 8.61  Med: 21.45 Max: 69.78
Current: 31
8.61
69.78
P/B 3.42
LZAGY's P/B is ranked lower than
61% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. LZAGY: 3.42 )
Ranked among companies with meaningful P/B only.
LZAGY' s P/B Range Over the Past 10 Years
Min: 0.74  Med: 2.08 Max: 3.98
Current: 3.42
0.74
3.98
P/S 1.92
LZAGY's P/S is ranked higher than
57% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. LZAGY: 1.92 )
Ranked among companies with meaningful P/S only.
LZAGY' s P/S Range Over the Past 10 Years
Min: 0.63  Med: 1.50 Max: 2.58
Current: 1.92
0.63
2.58
PFCF 24.20
LZAGY's PFCF is ranked higher than
64% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.68 vs. LZAGY: 24.20 )
Ranked among companies with meaningful PFCF only.
LZAGY' s PFCF Range Over the Past 10 Years
Min: 6.16  Med: 20.87 Max: 210.54
Current: 24.2
6.16
210.54
POCF 15.21
LZAGY's POCF is ranked higher than
71% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.98 vs. LZAGY: 15.21 )
Ranked among companies with meaningful POCF only.
LZAGY' s POCF Range Over the Past 10 Years
Min: 3.47  Med: 10.13 Max: 36.17
Current: 15.21
3.47
36.17
EV-to-EBIT 21.62
LZAGY's EV-to-EBIT is ranked higher than
53% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.25 vs. LZAGY: 21.62 )
Ranked among companies with meaningful EV-to-EBIT only.
LZAGY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.8  Med: 19.20 Max: 32.6
Current: 21.62
9.8
32.6
EV-to-EBITDA 12.65
LZAGY's EV-to-EBITDA is ranked higher than
64% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.20 vs. LZAGY: 12.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
LZAGY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7  Med: 10.10 Max: 14.7
Current: 12.65
5.7
14.7
PEG 8.97
LZAGY's PEG is ranked lower than
81% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.71 vs. LZAGY: 8.97 )
Ranked among companies with meaningful PEG only.
LZAGY' s PEG Range Over the Past 10 Years
Min: 0.57  Med: 3.14 Max: 9.98
Current: 8.97
0.57
9.98
Shiller P/E 29.58
LZAGY's Shiller P/E is ranked higher than
71% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.56 vs. LZAGY: 29.58 )
Ranked among companies with meaningful Shiller P/E only.
LZAGY' s Shiller P/E Range Over the Past 10 Years
Min: 19.4  Med: 27.74 Max: 34.41
Current: 29.58
19.4
34.41
Current Ratio 1.21
LZAGY's Current Ratio is ranked lower than
83% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. LZAGY: 1.21 )
Ranked among companies with meaningful Current Ratio only.
LZAGY' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.31 Max: 1.84
Current: 1.21
0.97
1.84
Quick Ratio 0.63
LZAGY's Quick Ratio is ranked lower than
92% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. LZAGY: 0.63 )
Ranked among companies with meaningful Quick Ratio only.
LZAGY' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 0.86 Max: 1.09
Current: 0.63
0.62
1.09
Days Inventory 117.00
LZAGY's Days Inventory is ranked lower than
60% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. LZAGY: 117.00 )
Ranked among companies with meaningful Days Inventory only.
LZAGY' s Days Inventory Range Over the Past 10 Years
Min: 95  Med: 107.93 Max: 123.17
Current: 117
95
123.17
Days Sales Outstanding 62.37
LZAGY's Days Sales Outstanding is ranked higher than
55% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. LZAGY: 62.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
LZAGY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.92  Med: 60.43 Max: 94.23
Current: 62.37
4.92
94.23
Days Payable 37.27
LZAGY's Days Payable is ranked lower than
68% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. LZAGY: 37.27 )
Ranked among companies with meaningful Days Payable only.
LZAGY' s Days Payable Range Over the Past 10 Years
Min: 29.47  Med: 37.08 Max: 53.87
Current: 37.27
29.47
53.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.81
LZAGY's Dividend Yield is ranked higher than
59% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. LZAGY: 1.81 )
Ranked among companies with meaningful Dividend Yield only.
LZAGY' s Dividend Yield Range Over the Past 10 Years
Min: 0.96  Med: 2.19 Max: 6.38
Current: 1.81
0.96
6.38
Dividend Payout 0.61
LZAGY's Dividend Payout is ranked lower than
76% of the 51 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. LZAGY: 0.61 )
Ranked among companies with meaningful Dividend Payout only.
LZAGY' s Dividend Payout Range Over the Past 10 Years
Min: 0.22  Med: 0.45 Max: 1.29
Current: 0.61
0.22
1.29
Forward Dividend Yield 1.81
LZAGY's Forward Dividend Yield is ranked higher than
59% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.49 vs. LZAGY: 1.81 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.29
LZAGY's Yield on cost (5-Year) is ranked higher than
59% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.58 vs. LZAGY: 2.29 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
LZAGY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.21  Med: 2.77 Max: 8.07
Current: 2.29
1.21
8.07
3-Year Average Share Buyback Ratio -0.20
LZAGY's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.80 vs. LZAGY: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LZAGY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.4  Med: -0.15 Max: 2.2
Current: -0.2
-3.4
2.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.50
LZAGY's Price/Tangible Book is ranked higher than
59% of the 218 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. LZAGY: 3.50 )
Ranked among companies with meaningful Price/Tangible Book only.
LZAGY' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.27  Med: 8.48 Max: 47.54
Current: 3.5
2.27
47.54
Price/Projected FCF 1.85
LZAGY's Price/Projected FCF is ranked higher than
51% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.89 vs. LZAGY: 1.85 )
Ranked among companies with meaningful Price/Projected FCF only.
LZAGY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.57  Med: 2.14 Max: 2.88
Current: 1.85
1.57
2.88
Price/DCF (Earnings Based) 4.32
LZAGY's Price/DCF (Earnings Based) is ranked lower than
83% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.83 vs. LZAGY: 4.32 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.38
LZAGY's Price/Median PS Value is ranked lower than
66% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. LZAGY: 1.38 )
Ranked among companies with meaningful Price/Median PS Value only.
LZAGY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.44  Med: 0.96 Max: 1.52
Current: 1.38
0.44
1.52
Price/Graham Number 8.83
LZAGY's Price/Graham Number is ranked lower than
90% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. LZAGY: 8.83 )
Ranked among companies with meaningful Price/Graham Number only.
LZAGY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.17  Med: 2.71 Max: 7.22
Current: 8.83
1.17
7.22
Earnings Yield (Greenblatt) (%) 4.65
LZAGY's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. LZAGY: 4.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LZAGY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.1  Med: 5.20 Max: 10.2
Current: 4.65
3.1
10.2
Forward Rate of Return (Yacktman) (%) 5.82
LZAGY's Forward Rate of Return (Yacktman) (%) is ranked lower than
60% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. LZAGY: 5.82 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LZAGY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.1  Med: 3.50 Max: 17
Current: 5.82
-5.1
17

More Statistics

Revenue(Mil) $3677
EPS $ 0.46
Beta0.96
Short Percentage of Float0.00%
52-Week Range $11.61 - 16.50
Shares Outstanding(Mil)520.15

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 3,814 3,960
EPS($) 0.65 0.76
EPS without NRI($) 0.65 0.76

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:LO3.Germany, O6Z.Singapore, LONN.Switzerland, 0QNO.UK,
Lonza Group AG was founded in 1897. The Company is a suppliers of biopharmaceuticals to the Pharma&Biotech and Specialty Ingredient markets. Its products and services range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens, from the manufacture of vitamin B compounds and organic personal care ingredients to agricultural services and products. The Company operates in two market segments: The Lonza Pharma&Biotech and The Lonza Specialty Ingredients. The Lonza Pharma&Biotech (LPB) market segment clusters all of its offerings for pharmaceutical markets, with strong Lonza positions in Custom Development, Custom Manufacturing and Bioscience Solutions. The Lonza Specialty Ingredients (LSI) market segment includes consumer-oriented offerings, with Consumer Care encompassing its Personal Care & Preservation, Nutrition and Hygiene offerings.
» More Articles for LZAGY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Lonza Group AG Earnings Analysis: 2015 By the Numbers Feb 02 2016
Lonza Reports Strong Sales and Profit Growth in 2015 Jan 27 2016
Lonza Consumer Care Expands Its Distribution Relationship with Azelis Americas Jan 19 2016
Lonza Consumer Care Announces Appointment of Dr. Jamie Hawkes FRSC as Head of Global Hair Care... Jan 19 2016
Lonza Expands Single-Use Manufacturing Capacity in Slough (UK) Facility to Meet Customer Demand Jan 13 2016
Lonza Further Strengthens QC Insider™ Toolbox with Launch of e-Learning Modules for Endotoxin... Jan 12 2016
Lonza to Showcase Automation Solutions for Transfection and Endotoxin Testing Technologies at... Jan 06 2016
Lonza Announces Change in Executive Committee Membership Dec 14 2015
Lonza Successfully Tackles the Myths About Salt-Water Pools Dec 08 2015
Lonza Announces Second Global Endotoxin Testing Summit – and Another Opportunity to “Flip”... Dec 03 2015
Lonza Announces Second Global Endotoxin Testing Summit – and Another Opportunity to “Flip”... Dec 02 2015
Lonza Consumer Care Launches Preferred Fragrance Program for EPA-Registered Formulations Nov 17 2015
Lonza Reports Positive Momentum in Q3 and Continues Path of Stabilization Oct 30 2015
Lonza to Host Free Webinar on Integrated QC Processes and Data Integrity Oct 16 2015
Lonza Authors Recent Publication on Availability of cGMP-Manufactured Human Induced Pluripotent Stem... Oct 15 2015
Lonza to Host Free Webinar on 3D Cell Culture Oct 12 2015
Lonza and Benitec Enter Agreement to Develop Scalable AAV Manufacturing Process for ddRNAi... Oct 07 2015
Recent Publications Demonstrate the Extended Versatility and Expanded Applications of Lonza’s... Oct 06 2015
Lonza and Lamberti Form Commercial Collaboration in South America To Serve Personal Care Markets Sep 24 2015
Lonza and Lamberti Form Commercial Collaboration in South America To Serveve Personal Care Markets Sep 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK